CStone Pharmaceuticals (HKSE:02616) EPS (Basic): HK$-0.34 (TTM As of Dec. 2025)


HKSE:02616 CStone Pharmaceuticals HKSE:02616
56 GF Score
Price HK$4.69
GF Value HK$1.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals EPS (Basic)?

CStone Pharmaceuticals HKSE:02616 -3.89% 56 EPS (Basic) is HK$-0.34 as of Dec. 2025. GuruFocus rates HKSE:02616 with a GF Score™ of 56/100 and a GF Value™ of HK$1.13 (Significantly Overvalued). The stock has 7 warning signs investors should review.

CStone Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.11. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.34.

CStone Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.34.

CStone Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.11. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.34.

During the past 3 years, the average EPS without NRI Growth Rate was 24.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 38.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, CStone Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 65.50% per year. The lowest was -137.40% per year. And the median was 22.20% per year.

CStone Pharmaceuticals  (HKSE:02616) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CStone Pharmaceuticals EPS (Basic) Related Terms

CStone Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for CStone Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals EPS (Basic) Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.02 -0.86 -0.32 -0.08 -0.34

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 0.01 -0.09 -0.23 -0.11
HKSE:02616
56GF Score
CStone Pharmaceuticals HKSE:02616
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CStone Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CStone Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-482.768-0)/1388.401
=-0.35

CStone Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-184.29-0)/1462.663
=-0.13

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.34 mean?
CStone Pharmaceuticals (HKSE:02616) has a EPS (Basic) of HK$-0.34 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CStone Pharmaceuticals and its competitors.
Is CStone Pharmaceuticals' EPS (Basic) too high?
CStone Pharmaceuticals' current EPS (Basic) is HK$-0.34. Overall, CStone Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
CStone Pharmaceuticals' EPS (Basic) of HK$-0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CStone Pharmaceuticals and its competitors. CStone Pharmaceuticals's current EPS (Basic) is HK$-0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (HKSE:02616) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.13, compared to a current price of HK$4.69 — trading 315% above its estimated fair value. The current EPS (Basic) is HK$-0.34. CStone Pharmaceuticals' overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For CStone Pharmaceuticals (HKSE:02616), the current EPS (Basic) is HK$-0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (HKSE:02616) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of HK$4.69 is trading 315% above its estimated GF Value™ of HK$1.13. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:02616:

  • EPS (Basic): HK$-0.34
  • GF Value™: HK$1.13 vs. price of HK$4.69 (315% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02616 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges CSPHF:USAPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
56GF Score

Get the complete analysis for HKSE:02616

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.69
Price
HK$1.13
GF Value